SLC7A5 and breast carcinoma: The ASCT2 antagonist V-9302 has demonstrated antitumor properties and has also shown the ability to impede breast cancer progression by enhancing T-cell activation.179 Moreover, co-administration of V-9302 with the glutaminase inhibitor CB-839 led to a significant reduction in human HCC xenograft growth.180 Additionally, in line with V-9302‘s antitumor activity and its inhibition of L-type amino acid transporter 1 (LAT1)-dependent neutral amino acid transport, LAT1 was found to be essential for tumorigenesis in KRAS mutant CRC models.181